Business
GSK Bolsters Pipeline with RAPT Buy, Expands RSV Vaccine to All Adults in Europe
GSK makes a dual strategic move, acquiring RAPT Therapeutics for its food allergy portfolio and securing broader European approval for its RSV vaccine Arexvy, reinforcing its focus on immunology and respiratory health.